Nevertheless, the proportion of EGFR+/ALK+ patients with at least 25% of tumor cells expressing PD-L1 who achieved an objective response was not substantially lower than that in EGFR−/ALK− patients (12.2% vs 16.4%) (59). The gene discussed is CD274; the disease is neoplasm.